A large number of drugs are transferred out of local medical insurance!

Since 2019, relevant departments in China have made it clear that the country will formulate the national basic medical insurance drug catalogue as the basis for medical insurance to pay for drugs in various places
.
Except for special regulations, the adjustment of Class B drugs will not be carried out in all regions, and the original provincial supplementary list drugs will be gradually digested within 3 years
.
It is reported that by 2022, China will realize the basic unification of the scope of basic medical insurance nationwide
.
According to the regulations of the National Medical Insurance Administration, provincial medical insurance departments should speed up the digestion of the original self-supplemented varieties to ensure that all digestion work is completed before June 30, 2022
.
At present, all provinces across the country are gradually carrying out the transfer or digestion of the medical insurance catalogue
.
For example, the notice issued by the Qinghai Provincial Medical Insurance Bureau on printing and distributing the supplementary drug digestion catalogue in Qinghai Province makes it clear that the remaining 98 varieties will be transferred in 2022, and medical insurance and work-related injury insurance will be suspended from January 1, 2023
.
On March 3, the Anhui Provincial Medical Insurance Bureau issued the "Announcement of the Digestive Varieties of the Original Provincial Supplementary Class B Drugs in Anhui Province in 2022".
Health Insurance Directory
.
The announcement period is from March 3, 2022 to April 3, 2022
.
It is understood that there are a total of 411 supplementary Class B drugs in the province, of which 328 drugs have been digested in batches in 2020 and 2021.
After comparison, it is determined that the remaining 83 drugs are to be digested, including 70 Western drugs, Chinese 13 medicines
.
In addition, the notice of the "Drug Digestion Adjustment Plan for Yunnan Province Beyond the National Medical Insurance Drug Catalog" issued by the Yunnan Provincial Medical Insurance Bureau shows that the province will simultaneously adjust the "2019 version of the National Drug Catalog" from 24:00 on June 30, 2020.
medicines, medicines that exceed the dosage forms paid by the national medical insurance, Chinese herbal decoction pieces that meet the state's clear non-payment, and national key monitoring drugs are subject to medical insurance reimbursement
.
According to the proportion and progress of digestive drugs in Yunnan Province, in the first year, there were 335 digestive drugs, accounting for 40.
023% of the digestive drugs, and medical insurance reimbursement ended at 24:00 on June 30, 2020; in the second year, there were 340 digestive drugs, accounting for 40.
621% of the digestive drugs %, the medical insurance reimbursement ends at 24:00 on June 30, 2021; in the third year, there are 162 digestive drugs, accounting for 19.
355%, and the medical insurance reimbursement ends at 24:00 on June 30, 2022
.
According to industry statistics, at least 349 drugs will be transferred out of medical insurance in the province next
.
Judging from the varieties that have been transferred out of medical insurance, there are many large varieties with more than 1 billion, such as cerebroside carnosine injection, cefoperazone tazobactam injection, oxiracetam injection, Yanhuning injection, sodium creatine phosphate injection , Sodium Potassium Magnesium Calcium Glucose Injection, Cefdizazine Injection, Dazhu Rhodiola Injection, Cefmandole Injection,
etc.
As these large varieties of medical insurance are transferred out, the industry expects that the market of related companies will also be affected
.
From January 2022, the new version of the National Medical Insurance Catalog has been launched, and a total of 74 drugs have been added to the catalog, including many that were approved to enter the medical insurance negotiation and selected shortly before June 30, 2021
.
Such as Haizheng Pharmaceutical's Haibo Maibu Tablets, the company said that due to the short time to market of Haibo Maibu Tablets, large-scale sales have not yet been achieved
.
Mengke Pharmaceutical, which is seeking to be listed on the Science and Technology Innovation Board, has its antibacterial drug product Contezolid Tablets entered into the medical insurance catalogue this time
.
For another example, BeiGene’s PARP (polyadenosine diphosphate ribose polymerase) inhibitor Pamiparib was approved in early May 2021, and Ellis’ fumetinib mesylate tablets were approved in March of the same year.
batch
.
The industry believes that with the dynamic adjustment of the medical insurance catalogue, a large number of expensive drugs with unclear efficacy will be excluded from medical insurance, and some drugs with high clinical value and obvious benefits to patients will have new opportunities to enter medical insurance
.
In this regard, the industry believes that pharmaceutical companies need to focus on innovative research and development, strive for more products to enter medical insurance, and enhance market competitiveness
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.